Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.87) per share. This is a 42.62 percent decrease over losses of $(0.61) per share from the same period last year.
Globalstar Q1: 79% Revenue Jump, Balance Sheet Improvements, Reiterated Outlook & More
Globalstar Inc (NYSE:GSAT) reported first-quarter FY23 sales growth of 78.9% year-on-year to $58.64 million, beating the consensus of $49.43 million. EPS…